PDF Minimally-invasive blood test could complement colonoscopy in high-risk LS patients who are non-compliant with colonoscopy screening recommendations or may develop precancerous lesions in the interval between colonoscopies Berlin (Germany), June 17, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary […]
Category: Press Releases
17. June 2019
New Clinical Data Support the Utility of Epi proColon® Blood Test for Colorectal Cancer (CRC) Screening in Patients with Lynch Syndrome (LS), the Most Common Hereditary CRC Syndrome
Read more
04. June 2019
Epigenomics AG to Participate in Raymond James Life Sciences and MedTech Conference in June
PDF Berlin (Germany) and San Diego, CA (U.S.A.), June 4, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced that company management will be presenting at the Raymond James Life Sciences and MedTech Conference in New York on Tuesday, June 18, 2019, at 1:50 pm (EDT) / 7:50 pm (CET) and invites […]
20. May 2019
New Report Shows CRC Screening Rates Increased When a Medically Underserved Population is Offered Epi proColon® Blood Test
PDF Data Presented at DDW 2019 Show 93.6% Acceptance Rate Among Patients Unwilling or Unable to Complete Other CRC Screening Tests Berlin (Germany) and San Diego, CA (U.S.A.), May 20, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation […]
09. May 2019
Epi proColon® Receives the 2019 Excellence in Molecular Diagnostics Award
PDF Corporate LiveWire acknowledges the importance of a patient-accepted CRC detection method to effectively diagnose colorectal cancer. Berlin (Germany) and San Diego, CA (U.S.A.), May 9, 2019 – Epigenomics AG is honored to have Epi proColon® recognized as the 2019 Excellence in Molecular Diagnostics award by Corporate LiveWire as part of the Innovation and Excellence […]
08. May 2019
Epigenomics AG Reports 2019 First Quarter Financial Results
PDF Berlin (Germany) und San Diego, CA (U.S.A.), May 8, 2019 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”) today announced the financial results (according to IFRS; unaudited) for the first quarter of the FY 2019. KEY HIGHLIGHTS Financial Total revenue increased to EUR 331 thousand (Q1 2018: EUR 309 thousand) primarily due to […]
03. May 2019
CMS accepts Epigenomics’ application for NCD review
PDF Berlin (Germany) and San Diego, CA (U.S.A.), May 3, 2019 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for Medicare & Medicaid Services (CMS) has accepted the company’s application for a National Coverage Determination (NCD) review of Epi proColon, Epigenomics’ blood test for colorectal cancer screening. The […]